Related Experiment Video
Updated: Jan 23, 2026

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors
Published on: February 28, 2021
BRCA1-associated protein (BAP1)-inactivated melanocytic tumors
Arianna J Zhang1, Patrick S Rush2, Hensin Tsao3,4
1Pathology Service, Massachusetts General Hospital, Boston, Massachusetts.
Abstract:
Although discussed using variable terminology, cutaneous BRCA1-associated protein (BAP1)-inactivated melanocytic tumor (BIMT) has been considered a discrete diagnostic entity since 2011. Here, we review the initial genomic studies that identified these distinct melanocytic tumors and the clinical and histopathological features that define these tumors. These epithelioid, predominantly dermal, and melanocytic tumors present as erythematous nodules and histopathologically have features that may overlap with Spitz nevi and nevoid melanoma. There is no sex predilection, and cutaneous BIMTs can appear at any age; however, in most familial (germline mutant) cases patients have multiple cutaneous tumors with a first diagnosis in the second or third decade of life; ocular melanoma and other tumors are increasingly identified in these kindreds with germline BAP1 mutation. These tumors have been described with a myriad of terms including: Wiesner nevus, nevoid melanoma-like melanocytic proliferation (NEMMP), BAP1 mutant Spitz nevus, BAP1 mutant nevoid melanoma, cutaneous BAPoma, and most recently cutaneous BIMT.
Insights
Cutaneous BRCA1-associated protein (BAP1)-inactivated melanocytic tumors (BIMTs) are distinct entities. Reviewing genomic and clinical data, these epithelioid tumors can mimic Spitz nevi and nevoid melanoma.
Area of Science:
- Dermatology
- Oncology
- Genetics
Background:
- Cutaneous BRCA1-associated protein (BAP1)-inactivated melanocytic tumor (BIMT) is a recognized diagnostic entity.
- BIMTs exhibit epithelioid morphology, predominantly dermal location, and can present as erythematous nodules.
- Histopathological features may overlap with Spitz nevi and nevoid melanoma, necessitating careful diagnosis.
Purpose of the Study:
- To review initial genomic studies identifying BIMTs.
- To delineate the clinical and histopathological features defining these tumors.
- To consolidate understanding of BIMTs and their varied terminology.
Main Methods:
- Review of initial genomic studies on BIMTs.
- Analysis of clinical presentation and histopathological characteristics.
- Compilation of diverse terminology used for these tumors.
Main Results:
- Genomic studies identified distinct melanocytic tumors now termed BIMTs.
- BIMTs are epithelioid, dermal tumors presenting as erythematous nodules.
- No sex predilection; can occur at any age, with familial cases showing multiple tumors and associated ocular melanoma.
Conclusions:
- BIMTs are a distinct diagnostic entity with specific genomic underpinnings.
- Clinical and histopathological features, though sometimes overlapping, aid in diagnosis.
- Germline BAP1 mutations are associated with familial BIMTs and increased risk of other tumors.
Related Concept Videos
Activation and Inactivation of G Proteins
X-Inactivation
Protein-protein Interfaces
Protein and Protein Structure
A protein's shape is critical to its function. For example, an enzyme...
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Conservation of Protein Domains Over Different Proteins
A limited set of protein domains often duplicate and recombine during evolution. These domains can be organized in different combinations to...

